It is a great privilege and honor to be here today, giv ing the second annual lecture on the history of psy chopharmacology. My friend Frank Ayd did such an admirable job with his lecture last year, on the early history, that I have had a hard problem finding gaps to fill . What I have finally chosen to do is to trace for you some of the early history, complete with anecdotes, which preceded our modern notions of psychology and pharmacology and then to tell you something of my own experiences and findings in the psychiatric world of the 1940s and 1950s, a world that was remarkably diff erent and simplistic compared to today. I also in tend to give you a subjective " oral history" of my own stumbling attempts to make some sense out of the vague and somewhat chaotic potpourri of ideas and pharmacologic approaches to psychiatric problems a half century ago.
Amy tal in Catatonia." I will discuss this paper in more detail later . After a careful search of the modern litera ture, I came to the conclusion that official general use of the term psychopharmacology in publications dates only to 1960, following a paper by Ross and Cole enti tled "Psychopharmacology," when also psychophar macology appears for the fIrst time as a free-standing item in the Cumulated Index Medicus. So, the period I will concentrate on will be pre-1960 (Freeman 1931; Thorner 1935; Ross and Cole 1960) .
HISTORY OF PSYCHOPHARMACOTHERAPY
Let us make a distinction between psychopharmaco therapy and psychopharmacology. The former is a clin ical discipline, based mainly on empirical observations, and the latter is a scientifIc discipline that is founded on systematic research. In the beginning, the achieve co therapeutics (Lehmann 1985) over the last 140 years. The time course is charted on the horizontal axis and the ordinate is divided into increments from one to ten, according to arbitrarily chosen values of the historical signilicance of the various discoveries. The year 1840 was chosen as the beginning, because it was then that the frrst major breakthrough occurred with the discov ery of general anesthesia. With nitrous oxide, ether, and chloroform, pain was conquered completely for the frrst time, at least for periods of time. In 1848, Morton suc cessfully performed the frrst ether anesthesia during a major surgical operation at the Massachusetts General Hospital. The new medical technology of general anes thesia, in turn, enabled surgery to make its own rapid progress. Further milestones in man's fIght against pain were the discovery in 1894 of cocaine by Koller and Sig mund Freud and the introduction of the all-purpose an algesic, acetylsalicylic acid, Aspirin, by Dreser in 1899.
Freud also was aware of the stimulating effects of cocaine on the central nervous system. He used the drug frequently himself and wrote to his fIancee how the boredom at certain evening parties in Paris was relieved by the pleasant action of cocaine (Freud 1960) . He also wrote that cocaine lifted him almost instantane ously out of a depression. However, it soon became clear to him that cocaine was neither a harmless stimu lant nor, as he had believed at frrst, a cure for patients who were addicted to morphine, but had addicting and dangerous properties of its own. He abandoned its use and from then on disliked and mistrusted psychoac tive drugs. However, he also predicted that many of the psychologic symptoms that at his time could only be treated with psychoanalysis would some day be treated with hormones or other chemical substances (Freud 1964) .
The frrst phase of psychopharmacotherapy, which had concentrated on the conquest of pain, was followed by a phase that focused on insomnia. In 1857, Locock introduced the bromides into therapy. They were ini· tially used as anticonvulsants, but later became the first medical tranquilizers. For many years they were pre scribed for insomnia and anxiety. However, they were not very effective and also highly toxic. Interestingly, their anticonvulsant action was suspected by Locock because potassium bromide was frrst known to reduce sexual libido. Since epilepsy, during much of the 19th century, was believed to be caused by excessive mastur· bation, it seemed to follow that bromides, by reducing sexual impulses, should also reduce epileptic seizures. One of many examples that a theory that makes no sense may, nevertheless, still lead to the desired resul ts.
In 1868, chloralhydrate was introduced into medi cal practice as a hypnotic and it proved to be so excel· lently suited for this purpose that today, more than a century later, it is still considered one of our best hyp notics. Incidentally, chloralhydrate provides another historical example of the right result having been gener· ated by a wrong theory. Liebreich, who introduced chloralhydrate as a hypnotic, had done so on the no tion that the drug would be metabolized in the bo dy to chloroform and thus put the patient to sleep. Chern· ically, this makes no sense, nevertheless, the drug works. That is, of course, all that really matters in psy· chopharmacotherapy; why it works is a question for the psychopharmacologists.
In 1903, Fischer and von Mering synthesized Veronal as a hypnotic barbiturate. It was, together with many barbiturate derivatives, to reign supreme for more than a generation as the remedy for insomnia. Today we rarely prescribe barbiturates since we are better informed about their high toxicity and addictive poten· tial. But in the frrst third of our century the many varieties of barbiturates, long-acting, intermediate, short-acting, ultrashort-acting ones were, besides chloralhydrate, the only respectable psychopharmaco therapeutic agents. Figure 1 . Successive milestones of modern psychopharmacotherapeutics. 
PSYCHOTHERAPEUTIC DRUGS

PSYCHIATRY IN THE 1940s
At the brink of World War II I parachuted from Europe into the new world of North American psychiatry. Let me sketch for you the picture of psychiatry in the early 1940s. We had Kraepelin's and Bleuler's guides to the diagnosis of the major psychoses, manic depressive dis order, and schizophrenia. We had only two theories to explain the rest of the psychiatric illnesses, the neu roses and personality disorders: Freud's psychoanaly sis and Pavlov's and Skinner's theories and fIndings on conditioning and learning.
Our two major therapies were insulin-induced hypoglycemic coma and electroconvulsive shock ther apies (ECTs) for schizophrenia and affective disorders; For the treatment of depression we routinely used oral tincture opii or injections of the then newly intro duced hematoporphyrine. The latter substance was supposed to photosensitize the organism and thus re duce the depression, an interesting forerunner of light therapy for seasonal affective disorder. However, hematoporphyrine didn't work. Finally, besides ECT,
we had a number of vitamins and hormones that we employed with hope, but without success, in what was then called involutional melancholia.
THE PREVAILING "ZEITGEIST" IN THE 1940s
In the 1940s mental illness was generally viewed as a hopeless stigma to be treated in hospitals with a vari ety of unspecrnc shock treatments. Alexander and Himwich 1939) . Some advanced research in neuroanatomy was car ried out at our hospital then that would be impossible to repeat today. Randomly selected psychotic patients had brain biopsies done by a neurosurgeon that re vealed some disorder of the oligodendroglia in schizo phrenia (Elvidge and Reed 1938) . (Remember that in those days there was no such thing as institutional re view boards.) We also did many air encephalograms on various patients, clearly as a &shing expedition, al though we knew since Jacobi's and Winkler's work in 1921 that schizophrenic patients tended to have en larged ventricles, either as a genetic or a progressive f eature (Jacobi and Winkler 1927) . We had one of the frrst electroencephalograph (EEG) machines in mental hospitals with Herb Jasper as our consultant. Several years before my arrival, a research study on manganese treatment of schizophrenia had been performed at the hospital . This treatment had been &rst proposed by Reiter and Bisgaard in Denmark, because Walbum had observed that small doses of manganese would prevent bacterial infections in animals. They reported 50% im provement in their schizophrenia patients. Our results showed that of 100 schizophrenia patients 36% of treated patients were discharged within a year compared to 18% of untreated. Improvement was partly measured by weight gain and reduction of the sedimentation rate. It is interesting to note that manganese, in toxic doses, is one of the few substances that may produce extrapy ramidal symptoms (Reiter 1929; Walbum 1925; Reed 
1929).
My &rst personal involvement with psychophar macology came when Collip, the Nobel Laureate of in sulin fame, gave me a new pituitary extract that he had produced and asked me to observe its effects on a few schizophrenia patients. I gave the extract, #47, as an oral medication to one of my acute schizophrenia pa tients and soon learned a lesson about placebo effects, coincidences, and confounding variables. On the 5th day of treatment my patient changed dramatically for the better, not only in behavior and insight but also on a quantitative association test. However, the im provement lasted for only 2 days, and a little later I l earned that the #47 pituitary extract had a strong alco hol content .
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In 1929, Loevenhart et al. had reported that amaz ing cerebral stimulation was occurring in catatonic pa tients who were exposed to carbon dioxide inhalation for several minutes (Loevenhart 1929) . Five years later, Hinsie et al ., inspired by this &nding, undertook a large and sophisticated study on the effects of oxygen and carbon dioxide on catatonic symptoms. The investiga tors placed 18 schizophrenic patients in a specially pre pared dormitory for 2% months. The dormitory was carefully sealed to maintain a 50% oxygen atmosphere, and some of the patients were also treated with peri odic short-lasting inhalations of carbon dioxide . The re searchers concluded that not the oxygen but the car bon dioxide had temporary therapeutic effects. Two of the patients had complete remissions. Although the authors had employed simple statistics in their study, they eschewed its use when they arrived at this delight fully expressed nonconclusion, "it can neither be affirmed nor denied that there was any relationship be tween treatment and the clinical condition . . . two facts are known; the patients received treatment and they became well."1t should be noted that the carbon diox ide treatment was so aversive that one chronically mute patient promised he would speak if he would be spared another treatment (Hinsie et al. 1934 ). See Figure 3 .
Thorner who in 1935 had introduced the term "psy chopharmacology," reported on an interesting study of sodium amytal in catatonic patients. He observed that catatonic uncommunicative patients would begin to talk and communicate quite freely when they were injected with a sodium amy tal solution that, according to a term used by Gullotta, "decatonized" them. Thorner explains this phenomenon on the basis of Sherrington's hierar chy of cerebral functions: the "super-inhibited," cata tonic brain is partially disinhibited and remains in that more normal state for several minutes or hours (Thorner 1935; Gullotta 1932) .
In the same year in which Thorner's paper ap peared, another somewhat enigmatic paper was pub lished about apomorphine in the experimental inhibi tion of catatonia. I could not locate this paper, so I do not know why the author chose apomorphine instead of carbon dioxide or a barbiturate for his experiments (Martinengo 1935) . Not much research at that time fo cused on the affective disorders, although the possible roles of cholesterol and carbohydrate metabolism were highlighted.
PERSONAL RESEARCH
One of my &rst systematic investigations, using a neu ropsychopharmacological tool, i.e., intravenous pen tobarbital, was a study of yawning. Jeellng them IItrongly to the power 91 sugge"tlon.
The pat"!Iltl! lIufCered from calat lon h •. , a Corm of demcntla praecox. Because nitrous oxide often produced euphoria, I
tried N20 inhalation as a treatment for depression.
That did not work. But N20 inhalation, which we used for up to 2 minutes in 100% anoxia-producing concen tration, did have the effect of frequently producing vivid dreams that could be reported after wakening. Some papers on the adjunctive use of this intervention with psychotherapy were published. When I personally un derwent this treatment for 2 minutes while my EEG was Placebo as a methodological instrument was, of course, discussed and used long before the clinical trials in psychopharmacology. As early as 1912 Hollingworth, who had been commissioned by the Coca Cola Co. to study the effects of caffeine on human performance, wrote that any good investigation of this kind should use placebos (Hollingsworth 1912) . In order to put the placebo to an extreme clinical test I chose three of our mute and most deteriorated schizophrenic patients in one of the back wards and treated them with a saline solution, taken from a mysteriously labeled bottle, and injected, in very small quantities, intracutaneously. The nurses and the patients were told that the substance was a new experimental hormone that I wanted to test.
The injection site on the skin was painted with mer curochrome that left an impressive red stain. I repeated these injections four times within 2 weeks. In the 3rd week two of the patients who had been mute for a long time started talking and asking rational questions. That convinced me of the power of the placebo.
I then started, together with a psychologist, a study of the "placebo proneness" of various test procedures.
We found, among other things, that the Word Fluency Test was less prone to be influenced by placebo than simple reaction time and that timed tests were less resis- Author's encephalogram before, after 2 minutes of 100% nitrous oxide inhalation, and 10 minutes after termi nation of inhalation.
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Not many clinical rating scales existed at the time, so we produced several of our own at the hospital, among others; a rating scale for patients who were receiving a lobotomy, a rating scale for psychotic pa tients, a projective rating scale and a depression rating scale, some of which were published (Lehmann and Dorken 1952; Lehmann et al. 1958 ). Somehow I always had reservations, and I still have, about rating scales that depend on value-tinged clinical judgement rather than on judgement-free pointer readings. Consequently, we developed various methods for the evaluation of psychoactive drug effects that were based on psycho logic performance tests (Lehmann and Csank 1957) . 
THE NEW DRUGS
I remember a group of students making hospital rounds with me in 1952 in Montreal. We were looking at two young schizophrenic patients gesturing excitedly to ward the ceiling from where they were hearing fright ening voices. One of the students asked afterwards, ''Will we ever get a pill to help these people?" I smiled patronizingly and replied that, unfortunately, it would never be as simple as "just a pill." Not more than a year later I read one Sunday morn ing some medical literature that a pharmaceutical de tail man had left with my secretary, saying: ''This is about some new drug that is so good that these papers Figure 6 . Psychopathologic profile of same patient shown in Figure 5 , now hypomanic, after 3 weeks following six ECT treatments.
will sell it." He was referring, I thought, rather arro gantly, to a few French publications about chlorproma zine, a substance that was supposed to produce pecu liar sedating effects in states of clinical excitement like a "chemical lobotomy." I was intrigued but very skeptical. In order to es tablish whether the sedative action of chlorpromazine was really qualitatively different from that of the tradi tional hypnotics I set up an experiment that is worth describing here briefly, as an illustration of the almost unbelievably naive way in which clinical research could still proceed only 38 years ago. I asked eight nurses to volunteer for the experiment that consisted in perform ing a few tests, i.e., reaction time, tapping speed, digit s p an for ward and digit-symbol-substitution before and 1 hour after receiving an oral dose of secobarbital and, on another day, before and 1 hour after an oral dose of chlorpromazine that was about equivalent to the secobarbital in its drowsiness-inducing effects. I then recorded roughly drawn scores of improved perfor mance, no change and decreased performance. For the secobarbital condition, I thought I needed only three subjects, since the results were so conspicuously differ ent from those under chlorpromazine. My evaluation of the results was made by inspection of these graphs with no attempt at statistical tests, of course, and I never confrrmed my impression by a duplication of the ex periment. In the tests some of my subjects performed actually better under the influence of chlorpromazine in a psychomotor and a cognitive test, but none of the three subjects on any test did so under secobarbital.
These results convinced me that chlorpromazine did indeed induce a new kind of sedation that seemed to be dissociated from the "dopiness," the impaired per formance that, we thought at that time, was an inher ent component of all drug-induced somnolence. See immediately set up a clinical trial of chlorpromazine with some psychotic patients, most of them schizo phrenic. Within days, some of the patients had stopped hallucinating and within 2 weeks a few were in remis sion and ready to leave the hospital. I assumed we were seeing a series of flukes, perhaps resulting from an ex tremely strange chance selection in the sample. It seemed almost as improbable as winning one million dollars twice in a lottery. Much as I wanted to believe what I was seeing, I didn't for a long time. Even in my correspondence with other clinicians in the United States working with the phenothiazines neither I, nor they, dared to attribute specific antipsychotic effects to these drugs. We thought it might be a new modifIcation of some sedating and inhibiting action, but we did not label the drugs anti psychotic. In 1956, when I was addressing the Cana dian Medical Association, I introduced the term "an tipsychotic" apologetically, and more as a metaphor than a designation.
It did not cross our minds that the new drugs might help the chronic back-ward patients, those who had not responded to insulin coma and ECT. However, we put a number of these ''hopeless'' patients on chlorproma zine for its symptomatic sedative effect and to our t?p . ... �. � . . ,�i�O�.\� c';IA H 0 U � � amazement, some of them actually went into remission. Again, it took us at least 2 years to accept the fact that at least some chronic schizophrenia patients were im· proving, even remitting, with phenothiazines. Now we wondered: might there be such a thing as long-term, perhaps indennite, protective main· tenance treatment, a real secondary prevention of rna· jar mental illness? It seemed too much of a long shot that these patients might be protected against recur· rences by continued administration of the new drug. There was no choice but to try it; and, to our amaze ment and delight, it worked.
Two or three months after we had started patients on chlorpromazine, I remember standing on the ward with a neurologist colleague and watching three pa· tients who walked with a shuffling gait, did not swing their arms, and had mask-like faces. We wondered about these peculiar side effects that looked very much like Parkinson's disease. But nobody had ever been able to produce Parkinsonism experimentally with any sub stance in animals or humans. The disease was known only in its idiopathic form. Yet here, for the nrst time, were drug-induced parkinsonian, extrapyramidal symptoms. Other investigators had made the same dis covery and it became clear: clinicians had done inciden· tally what experimental neuroscientists had not been able to do until then. In the absence of a solid pharmacologic explana tion of their action mechanisms I had some theories of my own in the early days of the antipsychotic drugs. Maybe the healing process of a psychosis was under taken by the patient's own psyche reorganizing itself, if it could only be freed from the disruptive interfer ence of excessive affects by a drug not grossly interfer ing with cognitive processes? Viewed in this way, some of the rapid remissions produced by chlorpromazine may be called self-recoveries, simply but powerfully aided by the drug. Seeing their action from this angle, I even proposed to call the drugs psychotostatic rather than antipsychotic (Lehmann 1956 ).
There seemed to be no need to abandon the psy choanalytic perspective altogether now that the exis tence of a physical substrate of schizophrenia had at last been established. Maybe the psychotic defenses of splitting, withdrawal, and decathexis were replaced un der pharmacotherapy by a movement toward external objects. Antipsychotic drugs do not induce disinhibi tion like anxiolytic sedatives; instead, they have selec tive inhibitory effects . Unlike anxiolytics that enforce defenses like regression, denial, and projection, chlor promazine seemed to facilitate the operation of more constructive defense mechanisms, such as isolation, ra tionalization, and sublimation, allowing the patient's ego to work through to a better adaptation to the real ity principle (Lehmann 1966) . Now that we had effective drugs for the treatment of schizophrenia, it was only natural to anticipate the discovery of antidepressant drugs in the near future. In the plane on my return from the 1957 World Psy chiatric Congress in Zurich I read Kuhn's paper on his results with imipramine. Back in Canada I phoned Geigy, the pharmaceutical company that had produced imipramine and asked for samples; however, the Cana dian Branch of Geigy had never heard of the drug. Ad mitting some embarrassment, they provided me with clinical samples flown in from Switzerland within a week and we started our fIrst clinical trials with depressed patients. At about the same time, Nate Kline developed his successful antidepressant treatment with an MAO inhibitor.
In contrast to the antipsychotic drugs whose prob able mechanism of action was not proposed until 1963 by Carlsson and Lindquist, an explanation for the mode of action of the antidepressants was offered almost as soon as their clinical efficacy was discovered. Now the therapeutic focus no longer was on unspecifIc coma, convulsion, or fever nor on defIcient oxygen metabo-lism, but on the processes involving specifIc neurotrans mitters in the brain. What puzzled clinicians and neu· roscientists at that time, and to some extent even now, was the long delay between the onset of antidepres sant therapy and its effects. Still imbued with the old physiologic concepts prevailing at the time, I thought that the brain-blood barrier might delay the therapeu· tic action of imipramine and conducted a clinical trial with pyrexia induced by a series of typhoid toxin injec· tions . This method, which was reported in a publica· tion, seemed to be successful in depressions that had resisted treatment with imipramine for more than 3 weeks; it also seemed to shorten the time between the beginnin g of therapy and its effects. I have not repeated the trial and, to my knowledge, nobody else has either. But perhaps somebody should (Lehmann 1960) .
The fIrst opening for a theoretical understanding of the action mechanisms of the new antidepressants came with the discovery, at the National Institute of Mental Health, that reserpine, another antipsychotic drug that sometimes induced depression, depleted presynaptic neurons of their biogenic amines, more specifIcally noradrenaline and serotonin. This led to the theory that a defIciency of biogenic amines might be a factor in the etiology of depressive disorders. The action mechanism of the antipsychotics was not understood until several years later when Carlsson and Lindquist reported, in 1963 , that all substances with antipsychotic action shared the common property of blocking dopaminergic neurons (Carlsson and Lind· quist 1963) . The role of these amines as neurotransmit· ters was a novel revolutionary concept and introduced a new paradigm into psychiatry. In this way the anti psychotic and antidepressant drugs served as a ''Rosett a stone" for the hieroglyphs of severe psychopathology and opened new avenues for the development of mod· ern neuroscience.
The 6th decade of our century had arrived and with it the spectacular development of the neurosciences and the official science of psychopharmacology.
